High Growth Tech Stocks To Watch In Australia September 2024
In This Article:
The Australian market has shown mixed performance recently, with the ASX200 closing up 0.3% at 8,099.9 points, driven by gains in the Materials and Real Estate sectors while Financials lagged behind. In this dynamic environment, identifying high-growth tech stocks becomes crucial as they offer potential for significant returns amid fluctuating economic indicators and sector performances.
Top 10 High Growth Tech Companies In Australia
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Clinuvel Pharmaceuticals | 22.41% | 27.42% | ★★★★★★ |
| Pureprofile | 14.94% | 80.73% | ★★★★★☆ |
| AVA Risk Group | 32.56% | 118.83% | ★★★★★★ |
| ImExHS | 20.47% | 111.20% | ★★★★★★ |
| DUG Technology | 10.90% | 32.21% | ★★★★★☆ |
| Pointerra | 56.62% | 126.45% | ★★★★★★ |
| Careteq | 34.13% | 126.60% | ★★★★★☆ |
| Wrkr | 36.31% | 100.29% | ★★★★★★ |
| Adveritas | 57.98% | 144.21% | ★★★★★★ |
| SiteMinder | 19.39% | 60.31% | ★★★★★☆ |
Click here to see the full list of 61 stocks from our ASX High Growth Tech and AI Stocks screener.
Let's explore several standout options from the results in the screener.
Nuix
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Nuix Limited offers investigative analytics and intelligence software solutions across various regions including the Asia Pacific, the Americas, Europe, the Middle East, and Africa, with a market cap of A$1.77 billion.
Operations: Nuix Limited generates revenue primarily from its Software & Programming segment, amounting to A$220.62 million. The company operates in regions such as Asia Pacific, the Americas, Europe, the Middle East, and Africa.
Nuix's revenue growth is forecasted at 11.8% per year, outpacing the Australian market's 5.3%. With earnings projected to grow by an impressive 40.2% annually, Nuix has become profitable this year, reporting a net income of AUD 5.03 million for FY2024 compared to a net loss of AUD 5.59 million the previous year. The strategic partnership with Veritone enhances their eDiscovery and compliance solutions, leveraging AI models to process vast amounts of evidentiary media efficiently.
-
Unlock comprehensive insights into our analysis of Nuix stock in this health report.
-
Evaluate Nuix's historical performance by accessing our past performance report.
Pro Medicus
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system (RIS) software and services to hospitals, imaging centers, and healthcare groups in Australia, North America, and Europe, with a market cap of A$17.52 billion.
Operations: Pro Medicus Limited generates revenue primarily from producing integrated software applications for the healthcare industry, amounting to A$161.50 million. The company focuses on providing imaging and radiology information system (RIS) software services to various healthcare entities across Australia, North America, and Europe.